• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双重支气管扩张剂联合术前康复对可手术治疗的肺癌及慢性阻塞性肺疾病的影响

Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease.

作者信息

Zhou Rong, Qin Yan, Hu Song, Xu Yangyang, Feng Chunlai

机构信息

Department of Respiratory and Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.

Department of Gastroenterology, Changzhou Maternal and Child Health Care Hospital, Changzhou, Jiangsu, China.

出版信息

Future Oncol. 2024 Dec;20(40):3471-3476. doi: 10.1080/14796694.2024.2430164. Epub 2024 Nov 28.

DOI:10.1080/14796694.2024.2430164
PMID:39607005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11776851/
Abstract

BACKGROUND

This study analyzed the application of dual bronchodilators in patients with non-small cell lung cancer (NSCLC) & chronic obstructive pulmonary disease (COPD) during the perioperative period.

RESEARCH DESIGN AND METHODS

A total of 100 patients with moderate to severe COPD who underwent thoracoscopic lobectomy were divided into two groups. The patients in the observation group (group O) were treated with umeclidinium/vilanterol and conventional treatment (oxygen therapy, assisted expectoration, respiratory rehabilitation training) during the perioperative period. The patients in the control group (group C) received conventional treatment. Lung function, arterial blood gas values, quality of life, postoperative adverse reactions, days of postoperative chest tube placement and hospitalization were assessed.

RESULTS

Before surgery, group O presented higher FEV1, FVC, PEF and MVV, elevated PO and reduced PCO, lower CAT scores compared with the group C ( < 0.05). The group O demonstrated fewer perioperative adverse reactions, and shorter days of postoperative chest tube and hospitalization compared with the group C ( < 0.05).

CONCLUSIONS

Perioperative inhalation of umeclidinium/vilanterol can effectively protect arterial blood gas and respiratory function in patients with LC complicated with COPD.

摘要

背景

本研究分析了双支气管扩张剂在非小细胞肺癌(NSCLC)合并慢性阻塞性肺疾病(COPD)患者围手术期的应用情况。

研究设计与方法

将100例行胸腔镜肺叶切除术的中重度COPD患者分为两组。观察组(O组)患者在围手术期接受乌美溴铵/维兰特罗及常规治疗(吸氧、辅助排痰、呼吸康复训练)。对照组(C组)患者接受常规治疗。评估肺功能、动脉血气值、生活质量、术后不良反应、术后胸腔闭式引流管留置天数及住院天数。

结果

术前,O组的第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰流速(PEF)及最大通气量(MVV)均高于C组,氧分压(PO)升高,二氧化碳分压(PCO)降低,慢性阻塞性肺疾病评估测试(CAT)评分低于C组(P<0.05)。与C组相比,O组围手术期不良反应较少,术后胸腔闭式引流管留置天数及住院天数较短(P<0.05)。

结论

围手术期吸入乌美溴铵/维兰特罗可有效保护肺癌合并COPD患者的动脉血气及呼吸功能。

相似文献

1
Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease.双重支气管扩张剂联合术前康复对可手术治疗的肺癌及慢性阻塞性肺疾病的影响
Future Oncol. 2024 Dec;20(40):3471-3476. doi: 10.1080/14796694.2024.2430164. Epub 2024 Nov 28.
2
Clinical and Economic Evaluation of Fluticasone Furoate/Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol Therapy in Maintenance Treatment-Naive Patients with COPD in the US.糠酸氟替卡松/乌美溴铵/维兰特罗与噻托溴铵/奥达特罗治疗美国初治慢性阻塞性肺疾病患者的临床与经济学评估
Int J Chron Obstruct Pulmon Dis. 2025 Feb 14;20:335-348. doi: 10.2147/COPD.S479504. eCollection 2025.
3
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.乌美溴铵/维兰特罗与其他支气管扩张剂治疗慢性阻塞性肺疾病的疗效比较:一项网络荟萃分析。
Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20.
4
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).溴化乌美溴铵对比安慰剂用于慢性阻塞性肺疾病(COPD)患者。
Cochrane Database Syst Rev. 2017 Jun 20;6(6):CD011897. doi: 10.1002/14651858.CD011897.pub2.
5
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.糠酸氟替卡松/乌美溴铵/维兰特罗(FF/UMEC/VI)三联疗法与其他 COPD 治疗药物的比较:一项网状荟萃分析。
Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17.
6
Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective.慢性阻塞性肺疾病中单一吸入器与多吸入器三联疗法的成本效益:德国医疗保健视角
Int J Chron Obstruct Pulmon Dis. 2025 Jun 19;20:2011-2022. doi: 10.2147/COPD.S492524. eCollection 2025.
7
A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.糠酸氟替卡松/维兰特罗联合用药治疗稳定期慢性阻塞性肺疾病的系统评价及荟萃分析
Pulm Pharmacol Ther. 2017 Feb;42:1-6. doi: 10.1016/j.pupt.2016.11.003. Epub 2016 Nov 15.
8
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.糠酸氟替卡松/乌美溴铵/维兰特罗与布地奈德/格隆溴铵/富马酸福莫特罗在美国慢性阻塞性肺疾病患者中的疗效比较
Adv Ther. 2025 Feb;42(2):1131-1146. doi: 10.1007/s12325-024-03088-1. Epub 2024 Dec 28.
9
In Silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients with COPD Using Functional Respiratory Imaging.使用功能性呼吸成像技术对慢性阻塞性肺疾病患者三种单吸入器三联疗法的计算机模拟肺沉积概况
Int J Chron Obstruct Pulmon Dis. 2025 Jun 27;20:2103-2116. doi: 10.2147/COPD.S510214. eCollection 2025.
10
Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.乌美溴铵/维兰特罗对肺功能影响的程度取决于单药治疗反应:两项随机对照试验的结果
Respir Med. 2016 Mar;112:65-74. doi: 10.1016/j.rmed.2016.01.001. Epub 2016 Jan 7.

引用本文的文献

1
PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.PARADIGM-PV:一项随机、多中心4期研究,旨在评估聚乙二醇干扰素α-2b治疗低危或高危真性红细胞增多症患者的疗效和安全性。
Ann Hematol. 2025 Jan;104(1):335-345. doi: 10.1007/s00277-025-06185-5. Epub 2025 Jan 13.

本文引用的文献

1
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
2
Advances and challenges in the treatment of lung cancer.肺癌治疗的进展与挑战。
Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. Epub 2023 Nov 16.
3
Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.开放三联和闭合三联吸入疗法治疗未控制哮喘患者的疗效比较。
Adv Respir Med. 2023 Jul 4;91(4):288-300. doi: 10.3390/arm91040023.
4
COPD and biologic treatment: state of the art.慢性阻塞性肺疾病与生物治疗:最新进展
Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):309-318. doi: 10.1097/ACI.0000000000000920. Epub 2023 Jun 20.
5
Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy.肺癌合并慢阻肺患者从抗 PD-1/PD-L1 治疗中获益。
Front Immunol. 2022 Dec 1;13:1038715. doi: 10.3389/fimmu.2022.1038715. eCollection 2022.
6
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.长效β2受体激动剂/长效抗胆碱能药物作为慢性阻塞性肺疾病的一线治疗:证据及指南推荐综述
J Clin Med. 2022 Nov 8;11(22):6623. doi: 10.3390/jcm11226623.
7
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview.慢性阻塞性肺疾病中 LAMA/LABA 吸入疗法联合治疗的药物治疗:临床概述。
Expert Rev Clin Pharmacol. 2022 Nov;15(11):1269-1281. doi: 10.1080/17512433.2022.2134113. Epub 2022 Nov 2.
8
From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis.从 COPD 到肺癌:关联机制、诊断、治疗和预后。
Int J Chron Obstruct Pulmon Dis. 2022 Oct 17;17:2603-2621. doi: 10.2147/COPD.S380732. eCollection 2022.
9
Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.长效毒蕈碱拮抗剂、长效β2-激动剂单独或联合应用与急性心肌梗死和卒中风险评估。
Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-1733. doi: 10.2147/COPD.S363997. eCollection 2022.
10
Systematic review and meta-analysis: value of venous blood gas in the diagnosis of acute exacerbation of chronic obstructive pulmonary disease in Emergency Department.系统评价和荟萃分析:静脉血气分析在急诊科诊断慢性阻塞性肺疾病急性加重中的价值。
Ann Palliat Med. 2022 Apr;11(4):1473-1481. doi: 10.21037/apm-22-336.